Cannabidiol Induces Rapid and Sustained Antidepressant-Like Effects Through Increased BDNF Signaling and Synaptogenesis in the Prefrontal Cortex
- 1.4k Downloads
Currently available antidepressants have a substantial time lag to induce therapeutic response and a relatively low efficacy. The development of drugs that addresses these limitations is critical to improving public health. Cannabidiol (CBD), a non-psychotomimetic component of Cannabis sativa, is a promising compound since it shows large-spectrum therapeutic potential in preclinical models and humans. However, its antidepressant properties have not been completely investigated. Therefore, the aims of this study were to investigate in male rodents (i) whether CBD could induce rapid and sustained antidepressant-like effects after a single administration and (ii) whether such effects could be related to changes in synaptic proteins/function. Results showed that a single dose of CBD dose-dependently induced antidepressant-like effect (7–30 mg/kg) in Swiss mice submitted to the forced swim test (FST), 30 min (acute) or 7 days (sustained) following treatment. Similar effects were observed in the Flinders Sensitive and Flinders Resistant Line (FSL/FRL) rats and the learned helplessness (LH) paradigm using Wistar rats. The acute antidepressant effects (30 min) were associated with increased expression of synaptophysin and PSD95 in the medial prefrontal cortex (mPFC) and elevated BDNF levels in both mPFC and hippocampus (HPC). CBD also increased spine density in the mPFC after 30 min, but not 7 days later. Intracerebroventricular injection of the TrkB antagonist, K252a (0.05 nmol/μL), or the mTOR inhibitor, rapamycin (1 nmol/μL), abolished the behavioral effects of CBD. These results indicate that CBD induces fast and sustained antidepressant-like effect in distinct animal models relevant for depression. These effects may be related to rapid changes in synaptic plasticity in the mPFC through activation of the BDNF-TrkB signaling pathway. The data support a promising therapeutic profile for CBD as a new fast-acting antidepressant drug.
KeywordsCannabidiol Antidepressant BDNF Prefrontal cortex
The authors acknowledge Flávia Fiacadori Salata and Per Fuglsang Mikkelsen for their helpful technical assistance.
Funding and Disclosure
This work was supported by research grants from the Research Foundation of the State of São Paulo (FAPESP, A.J.S., grant number 2015/01955-0;2012/17626-7); the National Council of Science and Technology, Brazil (CNPq) and National Institute of Science and Translational Medicine (CNPq, 465458/2014-9); the Coordination for the Improvement of Higher Education Personnel (CAPES); and Aarhus University Research Foundation (AU-UDEAS initiative: eMOOD). Gregers Wegener reported having received lecture/consultancy fees from H. Lundbeck A/S, Servier SA, Astra Zeneca AB, Eli Lilly A/S, Sun Pharma Pty Ltd., Pfizer Inc., Shire A/S, HB Pharma A/S, Arla Foods A.m.b.A., Alkermes Inc., and Mundipharma International Ltd.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 2.World Health Organization (WHO) (2017) Depression. website http://www.who.int/mediacentre/factsheets/fs369/en/.
- 3.Cleare A, Pariante CM, Young AH, Anderson IM, Christmas D, Cowen PJ, Dickens C, Ferrier IN et al (2015) Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines. J Psychopharmacol 29(5):459–525CrossRefPubMedGoogle Scholar
- 7.Ho SC, Jacob SA, Tangiisuran B (2017) Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: a qualitative study. PLoS One 12(6):e0179290. https://doi.org/10.1371/journal.pone.0179290. eCollection 2017
- 10.Zarate CA Jr, Niciu MJ (2015) Ketamine for depression: evidence, challenges and promise. World Psychiatry 14(3):348–350. doi: https://doi.org/10.1002/wps.20269.
- 16.Pandey GN, Ren X, Rizavi HS, Conley RR, Roberts RC, Dwivedi Y (2008) Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in post-mortem brain of teenage suicide victims. Int J Neuropsychopharmacol 11(8):1047–1061. https://doi.org/10.1017/S1461145708009000 CrossRefPubMedGoogle Scholar
- 24.Campos AC, Fogaça MV, Scarante FF, Joca SRL, Sales AJ, Gomes FV, Sonego AB, Rodrigues NS, Galve-Roperh I, Guimarães FS (2017) Plastic and neuroprotective mechanisms involved in the therapeutic effects of cannabidiol in psychiatric disorders. Front Pharmacol 23;8:269. doi: https://doi.org/10.3389/fphar.2017.00269.
- 26.El-alfy AT, Ivey K, Robinson K, Ahmed S, Radwan M, Slade D et al (2010) Antidepressant-like effect of Δ 9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L. Pharmacol Biochem Behav 95:434–442. https://doi.org/10.1016/j.pbb.2010.03.004 CrossRefPubMedPubMedCentralGoogle Scholar
- 27.Réus GZ, Stringari RB, Ribeiro KF, Luft T, Abelaira HM, Fries GR, Aguiar BW, Kapczinski F et al (2011) Administration of cannabidiol and imipramine induces antidepressant-like effects in the forced swimming test and increases brain-derived neurotrophic factor levels in the rat amygdala. Acta Neuropsychiatrica 23:241–248. https://doi.org/10.1111/j.1601-5215.2011.00579.x CrossRefPubMedGoogle Scholar
- 28.Linge R, Jiménez-Sánches L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A et al (2016) Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT 1A receptors. Neuropharmacology 103:16–26. https://doi.org/10.1016/j.neuropharm.2015.12.017 CrossRefPubMedGoogle Scholar
- 30.Schiavon A, Bonato J, Milani H, Guimarães F, Maria R, Weffort De Oliveira R (2016) Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Prog Neuro-Psychopharmacol Biol Psychiatry 64:27–34. https://doi.org/10.1016/j.pnpbp.2015.06.017 CrossRefGoogle Scholar
- 31.Esposito G, Scuderi C, Valenza M, Togna GI, Latina V, De Filippis D, Cipriano M, Carratù MR et al (2011) Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement. PLoS One 6(12):e28668. https://doi.org/10.1371/journal.pone.0028668 CrossRefPubMedPubMedCentralGoogle Scholar
- 33.Bisogno T, Hanus L, De Petrocellis L, Tchilibon S, Ponde DE, Brandi I et al (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br J Pharmacol 134(4):845–852CrossRefPubMedPubMedCentralGoogle Scholar
- 36.Mori MA, Meyer E, Soares LM, Milani H, Guimarães FS, de Oliveira RM (2017) Cannabidiol reduces neuroinfammation and promotes neuroplasticity and functional recovery after brain ischemia. Prog. Neuropsychopharmacol. Biol Psychiatry 3(75):94–105. https://doi.org/10.1016/j.pnpbp.2016.11.005 CrossRefGoogle Scholar
- 41.Paxinos G, Franklin KBJ (2001) The mouse brain in stereotaxic coordinates. 2. San Diego: Academic Press. https://doi.org/10.1111/j.1469-7580.2004.00264.x.
- 45.Pereira VS, Romano A, Wegener G, Joca SR (2015) Antidepressant-like effects induced by NMDA receptor blockade and NO synthesis inhibition in the ventral medial prefrontal cortex of rats exposed to the forced swim test. Psychopharmacology 232(13):2263–2273. https://doi.org/10.1007/s00213-014-3853-2 CrossRefPubMedGoogle Scholar
- 46.Campos AC, Ortega Z, Palazuelos J, Fogaça MV, Aguiar DC, Díaz-Alonso J, Ortega-Gutiérrez S, Vázquez-Villa H et al (2013) The anxiolytic effect of cannabidiol on chronically stressed mice depends on hippocampal neurogenesis: involvement of the endocannabinoid system. Int J Neuropsychopharmacol 16(6):1407–1419. https://doi.org/10.1017/S1461145712001502 CrossRefPubMedGoogle Scholar
- 50.Ampuero E, Rubio FJ, Falcon R, Sandoval M, Diaz-Veliz G, Gonzalez RE, Earle N, Dagnino-Subiabre A et al (2010) Chronic fluoxetine treatment induces structural plasticity and selective changes in glutamate receptor subunits in the rat cerebral cortex. Neuroscience 169(1):98–108. https://doi.org/10.1016/j.neuroscience.2010.04.035 CrossRefPubMedGoogle Scholar
- 52.Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, Li XY, Aghajanian G et al (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69(8):754–761. https://doi.org/10.1016/j.biopsych.2010.12.015 CrossRefPubMedPubMedCentralGoogle Scholar
- 56.Taniguchi N, Shinoda Y, Takei N, Nawa H, Ogura A, Tominaga-Yoshino K (2006) Possible involvement of BDNF release in long-lasting synapse formation induced by repetitive PKA activation. Neurosci Lett. 2;406(1–2):38–42.Google Scholar
- 57.Ghosal S, Bang E, Yue W, Hare BD, Lepack AE, Girgenti MJ, Duman RS (2018) Activity-dependent brain-derived neurotrophic factor release is required for the rapid antidepressant actions of scopolamine. Biol Psychiatry 1 83(1):29–37. https://doi.org/10.1016/j.biopsych.2017.06.017 CrossRefGoogle Scholar
- 58.Garcia LS, Comim CM, Valvassori SS, Réus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR et al (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuro-Psychopharmacol Biol Psychiatry 1 32(1):140–144CrossRefGoogle Scholar
- 59.Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 15; 475(7354):91–95. doi: https://doi.org/10.1038/nature10130.
- 63.Fogaça MV, Campos AC, Coelho LD, Duman RS, Guimarães FS (2018) The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: role of neurogenesis and dendritic remodeling. Neuropharmacology 3(135):22–33. https://doi.org/10.1016/j.neuropharm.2018.03.001 CrossRefGoogle Scholar
- 64.Diniz CRAF, Casarotto PC, Resstel L, Joca SRL (2018) Beyond good and evil: a putative continuum-sorting hypothesis for the functional role of proBDNF/BDNF-propeptide/mBDNF in antidepressant treatment. Neurosci Biobehav Rev 4(90):70–83. https://doi.org/10.1016/j.neubiorev.2018.04.001 CrossRefGoogle Scholar